Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PMCOL 412 > Caspases > Flashcards

Caspases Flashcards

1
Q

The most consistent risk factor for developing a neurodegenerative disorder is

A

increasing AGE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Aging begins when

A

development ends

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Damage from aging

A
  • Energy Dysregulation (insulin resistance, oxyradical production, glycation)
  • Molecular Damage (DNA oxidation/mutations, protein modifications, protein aggregation, decreased proteostatic mechanisms)
  • cell alterations (microglia activation, impaired detoxification, demyelination, impaired neurogenesis, synaptic dysfunction)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Adapting to aging

A
  • chaperons
  • growth factors
  • anti-apoptotic proteins
  • anti-oxidant enzymes
  • neurogenesis
  • growth of axons and dendrites
  • synaptogenesis
  • DNA repair
  • neural plasticity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Why doesn’t all aging lead to NDDs

A

because the body can adapt to damage caused by aging

Damage is balanced by plasticity and adaptation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Neural plasticity in aging

A

older people use different circuits than young people for the same task, adaptation due to damaged circuits with age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

WHy aging causes NDDs

A

When damage is increased and repair/plasticity is decreased due to either genetic or environmental factors
leads to accelerated cell death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

AGe-dependent effects of neurotoxin proteins: mHTT

A
  • mice striatums were injected with either mutant or normal HTT
  • mHTT caused neurodegeneration and the older the mouse the greater the loss
  • normal HTT caused no change and didn’t have different effects depending on age
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mechanisms of neurodegeneration

A

Failure in:

  • protein quality control: chaperones and proteasome (increased misfolding and aggregation)
  • autophagy-lysosome pathway
  • mitochondria metabolism: homeostasis and quality control (decreased energy + increased ROS –> no energy for proteostasis and increased damage)
  • excitotoxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

T/F: only neurons are implicated in NDD

A

FALSE
degen occurs in all brain cells (incl. astrocytes, glia, oligodendrocytes)
- cytokine, etc. release activates glia
- impaired glial function can occur due to abberant proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

T/F: transplanting neural stem cells works over the long term

A

FALSE
Short term: helpful, as neurons derived from these stem cells integrate and replace those lost
BUT over time as these neurons were exposed to a diseased environment, they will degen like their predecessors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Best therapeutic approaches for NDDs and why

A

Must target the cause of the disease (ex. the protein itself–mHTT, alpha-syn) b/c the damage occurs through many different pathways that attacking one pathway won’t effectively alter disease course.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Caspases and NDDS: old view

A

cell death occurs through caspase-mediated apoptosis

therefore blocking caspases will decrease cell death–but may be too late as it will not decrease cell dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Caspases and NDD: current view

A

Recent info suggests that caspases are active prior to and independent of apoptosis
therefore their inhibition may work earlier and help increase neuronal function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Caspases

A
  • cysteine aspartic acid-specific proteases
  • are proteases that have an essential Cys residue in their active site and require Asp at the substrate cleavage site.
  • Amino acids that occupy the P4 position are the most important determinant of individual caspases specificity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Initiator caspases: role

A

are usually activated by specific cellular or extracellular stimuli
cleave and activator effector caspase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Effector caspases: role

A

execute the apoptotic program by cleaving several intracellular proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Inflammatory caspases: role

A

are involved in activation of cytokines and modulation of immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Inflammatory caspases (numbers)

A

caspase 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Initiator caspases (numbers)

A

caspases 8 and 9

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Effector caspases (numbers)

A

caspases 3 & 6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Caspase structure

A

Cys residue in active is essential for protease activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Caspase binding

A

Asp in P1 position is essential cleavage

Note: P1 is the AA immediately prior to the cleavage site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Caspase binding specificity

A

AAs upstream from the cleavage site (P1, P2, P3, P4) determine substrate specificity
P4 (4 AAs prior to cleavage site) is the single most important determinant of caspase specificity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Activation of caspases

A

For initiator caspases: dimerization is sufficient for activation.
Executioner caspases: require proteolytic removal of the prodomain, and cleavage into large and small subunits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Caspases are expressed as…

A
  • inactive proenzyme (aka zymogen)
  • proenzyme is cleaved at caspase cleavage sequences (asp-X)
  • for executioners –> 2 large and 2 small subunits to form the active tetramer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Extrinsic pathway

A

Binding of FasL/TNFalpha to transmembrane death receptors –> recruitment of FADD that recruits + aggregates Cas 8 –> Cas8 autoprocessing and activation –> active Cas8 cleaves Cas7 + cas 3 –> cas 3 + 7 cleave cellular proteins –> apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

In some cases of extrinsic pathway

A

Cas 8 can cleave BID –> truncated BID (tBID) can promote mitochondrial cytochrome C release –> activates cas 9

similar to the intrinsic pathway events

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Intrinsic pathway: crucial event

A

mit outer memb permeabililzation controlled by the BCL-2 family of proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Intrinsic pathway

A

Cell stress activates BID/BIK/BIM etc (stress sensors) –> overcome antiapoptotic effects of BCL2 –> promotes oligomerization of BAX-BAK (pro-apoptotic proteins) taht form pores in the mit outer membrane –> allows cyt. c (and other proteins in it intermemb space) to leak into the cytosol –> cyt c release trigger apoptosome activation –> ca 9 activated –> ca 9 cleaves cas 3 and 7 –> cleavage of many cellular substartaes –> apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

How do we make sure apoptosis is prevented when we don’t want it

A

Cas 3 and 7 (effector caspases) are blocked in normal conditions due to their binding by XIAP –> prevents activation without cellular stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

How do we remove the ‘break’ on apoptosis

A

Omi/HTRA2 and Smac/Diablo bind to XIAP during cellular stress to remove the ‘break’ on apoptosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Once effector caspases are activated

A

once activated caspases (3, 6, 7) orchestrate the dismantling of cell structures through cleavage of specific substrates

34
Q

Dismantling of cell structure

A
  • by effector caspases

- through cleavage of various substrates: ICAD,

35
Q

ICAD

A

when cleaved releases an active DNASase molecule that cleaves DNA –> DNA fragmentation

36
Q

Nuclear fragmentation

A

by caspase-mediated cleavage of nuclear envelope proteins

37
Q

Phosphatidylserine (PS)

A
  • a phospholipid normally found in the inner leaflet of the plasma membrane but is flipped out during apoptosis and acts as an “eat me” signal to fibroblasts/macrophages/microglia for phagocytosis
38
Q

Cytoskeleton contraction in apoptosis

A

proteolysis of cytoskeleton regulator –> contraction of actin cytoskeleton –> plasma memb blebbling

39
Q

T/F caspases only apply to neurodegeneration and not development

A

FALSE
Caspases have a crucial role during neurodevelopment. Half of the neurons
generated during the development of the nervous system is eliminated by apoptosis to remodel brain structures and optimize synaptic connections.

40
Q

Deficiencies in these caspases etc. cause severe developmental abnormalities or death

A

Caspase 3, caspase 9, Apaf1 and cyt.c deficient mice die during embryonic or postnatal development and display severe brain abnormalities

41
Q

Non-apoptotic caspase-3 functions in neurons

A
  • Caspase 3 activity facilitates neurogenesis.
  • Involved in dendritic pruning.
  • Involved in synaptic plasticity.
  • Many proteins that have a role in synaptic plasticity are substrate of caspase 3.
  • Involved in learning and memory. Glutamate can induce caspase-3 activation without inducing cell death
42
Q

LTD occurs through

A

LTD occurs through internalization of AMPARs by GSK3-beta

43
Q

LTD

A

activity-dependent reduction in synaptic efficacy that normally lasts hrs or longer following a long patterned stimulus

44
Q

Reason for LTD

A
  • allow downregulation of synapses

- to prevent hitting a wall of max efficacy and preventing further learning

45
Q

LTD mechanism

A

NMDAR activation by glut –> calcium entry and activation of calcineurin –> active calciuneurin dephosphorylates (intiates) BAD –> BAX-BAK form pore in MIT –> cyt c release –> cas 9 activation –> cas 3 cleaves AKT –> removes break on GSK3-beta –> AMPAR endocytosis

46
Q

Cas 3 role in LTD: precise mechanism

A

AKT normally suppresses LTD by inhibiting GSK3-beta –> Cas 3 cleaves AKT –> GSK3-beta active –> AMPAR endocytosis

47
Q

Cas 3: basics

A

Caspase 3 stimulates AMPA receptors
internalization and long-term depression
(LTD).

48
Q

LTD vs. apoptosis

A
  • Lower levels of Cas 3 activation and transient activation

- enough cas 3 activation for AKT cleavage but not enough for apoptosis

49
Q

Apoptosis and Neurodegenerative Diseases

A
  • Apoptosis is a common form of cell death occurring in ND (but not the only one)
  • Caspases are activated in many NDDs, before cell death occurs (and independently from it)
  • Caspase 3 and 6 can contribute to pathogenesis based on their nonapoptotic functions in modulation of learning and memory and protein cleavage, respectively
  • Inhibitors of caspases and apoptosis may be beneficial in the treatment of neurodegenerative disorders.
50
Q

Cas 3 in AD

A
  • Cas 3 is activated above normal levels in AD mice, notably after 3 months
  • Overactivation of Cas 3 at the synapse may lead to cognitive deficits in AD
51
Q

Caspase 6–unusual because of…

A
  • Caspase 6 is classified as an executioner caspase, however, it is also associated with inflammation.
  • Caspase 6 activation requires removal of the pro-domain of the zymogen and further cleavage to generate the large and the small subunit and expose the active site to the substrates
52
Q

Activation of cas 6

A
  • Can be activated by caspase 3 or 1, but can also self-activate
  • A certain level of activation is also
    possible without cleavage, through a conformational change in the zymogen, which makes the active site accessible.
53
Q

Cas 6 structure

A
  • It has been proposed that is in a dynamic equilibrium between a tetramer (off-state) and a dimer (on state).
  • dimers will self-cleave = be active
  • tetramer active site is hidden = inactive
54
Q

Cas 6 alpha vs beta

A

1) In the alpha-helical structure, a hydrophobic patch is exposed that helps with the initial recruitment of substrates
2) a region of cas 6 continuously interconvert from alpha-helical structure to a beta-strand structure
3) substrate binding stabilizes the beta-strand conformation, which in turn promotes enzyme activity

55
Q

Cas 6 modulation: therapy

A

alterations in beta/alpha structure of cas 6 can alter function:

  • stabilize beta structure = increase activity
  • stabilize alpha-helix = decreased activity
56
Q

Issues with therapeutic modulation of Cas 6 structure

A

alpha helix structure is needed to recruit substrates and stabilizes beta-strand
if we increase beta-strand without alpha strand = no stabilization or binding

57
Q

Increased Cas 6 in AD: old view

A
  • unclear why cas 6 is increased in AD
  • proposed that n-terminal fragment of APP (N-APP) generated by cleavage by beta-secretase or Abeta activate DR-6 receproe –> DR-6 receptor normally activates cas 6 for neuronal axon trimming etc. –> potential hijacking of these processes causing axonal degradation and cell death
58
Q

Cas 6 in AD:

A
  • Caspase 6 expression is upregulated in AD. BUT exact mechanism unknown
  • APP is a substrate for caspase 6. Cleavage by caspase 6 facilitates further production of Aβ
59
Q

Increased Cas 6 in AD: new view

A
  • cell death can occur without DR-6 –> suggests other mechanisms of cas 6 activation in AD
60
Q

Increased Cas 6 in AD: new view

A
  • cell death can occur without DR-6 –> suggests other mechanisms of cas 6 activation in AD
61
Q

Cas 6 in HD

A
  • Active caspase 6 is detected in HD brains
  • Caspase 6 cleaves mHTT generating a highly toxic fragment
  • mHTT 586 fragments binds to caspase 6 zymogen and promotes a conformation capable of substrate binding, also facilitating full caspase activation –> increased Cas 6 activity
62
Q

Cas 6 reisstant mice in HD

A

Caspase-6 resistant mice (C6R) generated by site-directed mutagenesis show decreased pathology compared to regular HD mice (HD53)

63
Q

Cas 6 drugs in HD

A

Drugs that affect caspase-6-mediated cleavage of mutant HTT may have therapeutic application to slow down HD
progression

64
Q

Targeting apoptosis in CANCER

A

Goal is to INCREASE APOPTOSIS of cancer cells
Main approaches:
- Compounds that inhibit Bcl-2
-Antisense oligonucleotides to decrease Bcl2 expression
-Small molecules that activate caspases
-Inhibitors of XIAP

65
Q

Targeting apoptosis in NDDs

A

Goal is to DECREASE APOPTOSIS

  • Caspase inhibitors (by Binding to the active site or Allosteric inhibitors)
  • Minocycline
66
Q

Minocycline

A

Second-generation, semi-synthetic tetracycline analog.

It is highly lipophilic and penetrates the BBB

67
Q

Minocycline mode of action

A

+ Anti-apoptotic action
- Inhibits expression of caspase 1 and 3
- Inhibits mitochondria depolarization (that occurs during apoptosis)
- Increases expression of anti-apoptotic protein (Bcl-2)
+ Anti-inflammatory action
- Modulation of microglia and peripheral immune cells
+ Modulates protein aggregation
+ Inhibits the activity of matrix metalloproteinases (proteins that contribute to NDDs)

68
Q

Minocycline in clinical trials

A
  • One small clinical trials in HD patients showed improvement in treated patients
  • A second small trial did not confirm efficacy
  • A third larger trial was interrupted because of serious hyperpigmentation side effects occurring after 1 year of treatment
  • A large clinical trial for the use of minocycline in ALS was halted due to worsening of the conditions in patients treated with the drug
  • Seems to work in MS
69
Q

Minocycline in MS

A

Phase III trial in MS patients is ongoing.
A previous phase II trial in combination with Copaxone (glatiramer acetate) showed 60% reduction in new lesions in MS patients.

70
Q

Peptidomimetic caspase inhibitors

A
  • Bind the active site. Bulky, electrophilic or anionic

- include Z-VAD and IDN-6556

71
Q

Z-VAD

A
  • Pan-caspase inhibitor (inhibits many caspases)
  • BUT Highest affinity for caspase 3 and 7
  • Clinical development was discontinued because Z-VAD catabolites (mainly fluoroacetate) produce liver damage.
72
Q

IDN-6556

A
  • Peptidomimetic irreversible pan-caspase inhibitor.
  • Well tolerated in phase I and II clinical trial for liver transplantation and hepatites C infection. Developed by Pfizer.
73
Q

Small molecules caspase inhibitors: why and examples

A
  • Developed to overcome limitations of peptidomimetics

incl. VX-799, M-826

74
Q

VX-799

A
  • a small molecule pan-caspase inhibitor.

- In clinical trial for sepsis. Effective in preventing neuronal cell death in vitro.

75
Q

M-826

A
  • Reversible small molecule inhibitor of caspase 3 and 7.
  • Developed by Merck Frosst.
  • Decreases brain tissue damage in murine models of hypoxia-ischemia
76
Q

Specificity in Caspase inhibitor

A

In general, developing specific caspase inhibitors that target the active site has been proven to be difficult, because the active site is very conserved across caspases
Try allosteric inhibitors

77
Q

Genentech/UCSF team to target Cas 6

A

Genentech/UCSF team leads drug discovery efforts to develop Cas 6 inhibitors:

  • small molecules allosteric inhibitors
  • peptide allosteric inhibitors
78
Q

Compound 5

A
  • Compound 5 binds pro-caspase 6, but not the active enzyme, and blocks caspase 6 self-activation.
  • It is one of the first reversible nM-affinity ligands for the dimer interface site of any caspase family member.
  • The molecular characteristics of this compounds, which is neither electrophilic nor anionic, make it a much more attractive lead compound for clinical development.
79
Q

What makes Compound 5 a better drug than previous case inhibitor

A
  • allosteric inhibitor–binds to dimer interface which is less conserved across caspases –> specificity
  • neither electrophilic nor anionic –> better as a drug/ for drug delivery
80
Q

Pep419

A
  • a small peptide that binds caspase 6 and stabilizes/promotes tetramers formation through a novel allosteric mechanism.
  • promotes the tetrameric (i.e. inactive) form–acts as a non-competitive inhib of active cas 6
  • Highly specific to caspase-6
81
Q

How allosteric inhibitors were found for cas 6

A

High-throughput screen (>22K compounds
screened) with HTT as a substrate –>
Identification of a group of irreversible
allosteric C6 inhibitors that bind to the dimer
interface.

PMCOL 412 (35 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions